Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000401145

Medchemexpress LLC Upadacitinib | 1310726-60-3 | 100.0% | 380.37 | 100 MG
SDP

Catalog No. 5000401145
Encompass_Preferred

Upadacitinib (ABT-494) is a potent, orally active, and selective Janus kinase 1 (JAK1) inhibitor with an IC50 of 43 nM. It demonstrates approximately 74-fold selectivity for JAK1 over JAK2 (IC50=200 nM) and 58-fold selectivity over JAK3 in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be utilized for research related to several autoimmune disorders.

  • Potent, orally active, and selective JAK1 inhibitor
  • Displays approximately 74-fold selectivity for JAK1 over JAK2 (IC50=200 nM)
  • Displays approximately 58-fold selectivity for JAK1 over JAK3
  • May offer an improved benefit-risk profile in patients with RA due to enhanced selectivity for JAK-1 over JAK-2 and JAK-3
  • Demonstrates efficacy in rat arthritis models

Catalog No. 50-004-01145 Supplier Medchemexpress LLC Supplier No. HY19569100MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Upadacitinib (ABT-494) is a potent, orally active, and selective Janus kinase 1 (JAK1) inhibitor with an IC50 of 43 nM. It demonstrates approximately 74-fold selectivity for JAK1 over JAK2 (IC50=200 nM) and 58-fold selectivity over JAK3 in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be utilized for research related to several autoimmune disorders.

  • Potent, orally active, and selective JAK1 inhibitor
  • Displays approximately 74-fold selectivity for JAK1 over JAK2 (IC50=200 nM)
  • Displays approximately 58-fold selectivity for JAK1 over JAK3
  • May offer an improved benefit-risk profile in patients with RA due to enhanced selectivity for JAK-1 over JAK-2 and JAK-3
  • Demonstrates efficacy in rat arthritis models

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.